Rachel Erlich

20.8k total citations · 1 hit paper
39 papers, 2.1k citations indexed

About

Rachel Erlich is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Rachel Erlich has authored 39 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 12 papers in Molecular Biology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Rachel Erlich's work include Cancer Genomics and Diagnostics (11 papers), Lung Cancer Treatments and Mutations (10 papers) and Acute Myeloid Leukemia Research (5 papers). Rachel Erlich is often cited by papers focused on Cancer Genomics and Diagnostics (11 papers), Lung Cancer Treatments and Mutations (10 papers) and Acute Myeloid Leukemia Research (5 papers). Rachel Erlich collaborates with scholars based in United States, Netherlands and Israel. Rachel Erlich's co-authors include Tony Kouzarides, Robert Schneider, Stuart L. Schreiber, B Bernstein, Jun S. Liu, Siraj M. Ali, Jeffrey S. Ross, Vincent A. Miller, Alexa B. Schrock and Philip J. Stephens and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Rachel Erlich

38 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Methylation of histone H3 Lys 4 in coding regions of active genes

2002 595 citations Rachel Erlich et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rachel Erlich United States	19	1.0k	592	585	343	337	39	2.1k
Aaron R. Thorner United States	26	1.1k 1.1×	694 1.2×	582 1.0×	92 0.3×	524 1.6×	55	2.2k
Matthew Liebers United States	6	1.9k 1.9×	406 0.7×	431 0.7×	60 0.2×	252 0.7×	8	2.4k
Daoud Sie Netherlands	26	1.6k 1.6×	451 0.8×	204 0.3×	374 1.1×	1.2k 3.6×	55	2.6k
Mateusz Opyrchal United States	23	694 0.7×	1.0k 1.7×	328 0.6×	406 1.2×	272 0.8×	101	1.8k
Tadashi Hongyo Japan	18	364 0.4×	689 1.2×	278 0.5×	246 0.7×	158 0.5×	43	1.4k
Sandrine Sander Germany	15	1.6k 1.6×	343 0.6×	63 0.1×	441 1.3×	359 1.1×	20	2.2k
Li Hu China	20	516 0.5×	922 1.6×	100 0.2×	376 1.1×	184 0.5×	54	1.6k
Magnus Sundström Sweden	24	580 0.6×	524 0.9×	268 0.5×	309 0.9×	300 0.9×	40	1.5k
Tobias Grob Germany	25	992 1.0×	954 1.6×	378 0.6×	83 0.2×	396 1.2×	55	2.2k
Channing Yu United States	17	1.7k 1.7×	327 0.6×	474 0.8×	906 2.6×	255 0.8×	30	3.5k

Countries citing papers authored by Rachel Erlich

Since Specialization

Citations

This map shows the geographic impact of Rachel Erlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Erlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Erlich more than expected).

Fields of papers citing papers by Rachel Erlich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Erlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Erlich. The network helps show where Rachel Erlich may publish in the future.

Co-authorship network of co-authors of Rachel Erlich

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Erlich. A scholar is included among the top collaborators of Rachel Erlich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Erlich. Rachel Erlich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Riess, Jonathan W., Margaret E. McLaughlin-Drubin, Richard S.P. Huang, et al.. (2023). Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles. The Oncologist. 29(2). e224–e236. 4 indexed citations

Husain, Hatim, Dean C. Pavlick, Bernard J. Fendler, et al.. (2022). Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples. JCO Precision Oncology. 6(6). e2200261–e2200261. 58 indexed citations

Janovitz, Tyler, Douglas A. Mata, Meagan Montesion, et al.. (2022). Activating IGF1R hotspot non-frameshift insertions define a novel, potentially targetable molecular subtype of adenoid cystic carcinoma. Modern Pathology. 35(11). 1618–1623. 2 indexed citations

Morfouace, Marie, Vassilis Golfinopoulos, Dexter X. Jin, et al.. (2020). First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN. ESMO Open. 5(6). e001075–e001075. 13 indexed citations

Madison, Russell W., Douglas I. Lin, Alexa B. Schrock, et al.. (2020). Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. Oncology. 98(12). 905–912. 36 indexed citations

Hassan, Mohammed, Erin Butler, Angshumoy Roy, et al.. (2019). Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib. Molecular Case Studies. 5(5). a004440–a004440. 10 indexed citations

Chu, Lisa P., Christine A. Parachoniak, Jeffrey P. Gregg, et al.. (2019). MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation. The Oncologist. 24(10). 1305–1308. 5 indexed citations

Lin, Douglas I., Justin Allen, Jonathan L. Hecht, et al.. (2019). SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association. Modern Pathology. 32(11). 1675–1687. 49 indexed citations

Pavlick, Dean C., Mark R. Rosenzweig, Rachel Erlich, et al.. (2018). MA16.05 MET Kinase Domain Rearrangements (KDRE) in Non-Small Cell Lung Cancer (NSCLC) Identified Through Comprehensive Genomic Profiling (CGP). Journal of Thoracic Oncology. 13(10). S412–S412. 4 indexed citations

10.

Tarlock, Katherine, Yuting He, James Sun, et al.. (2017). Recurrent Copy Number Variants Are Highly Prevalent in Acute Myeloid Leukemia. Blood. 130. 3800–3800. 1 indexed citations

11.

Gornstein, Erica, Jon Chung, Laurie M. Gay, et al.. (2017). BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. Clinical Breast Cancer. 18(2). 184–188. 36 indexed citations

12.

Parachoniak, Christine A., Andrew Rankin, Ryan J. Hartmaier, et al.. (2017). Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring anSTK11variant. Molecular Case Studies. 3(5). a000778–a000778. 19 indexed citations

13.

Heilmann, Andreas, Alexa B. Schrock, Jie He, et al.. (2017). Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia. Leukemia. 31(9). 1989–1992. 13 indexed citations

14.

Thorpe, Lauren M., Alexa B. Schrock, Rachel Erlich, et al.. (2016). Significant and durable clinical benefit from trastuzumab in 2 patients with HER2‐amplified salivary gland cancer and a review of the literature. Head & Neck. 39(3). E40–E44. 33 indexed citations

15.

Schrock, Alexa B., Garrett M. Frampton, James Suh, et al.. (2016). Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. Journal of Thoracic Oncology. 11(9). 1493–1502. 269 indexed citations

16.

Subbiah, Vivek, Oliver Holmes, Kyle Gowen, et al.. (2016). Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. Oncology. 91(6). 348–353. 28 indexed citations

17.

Chung, Jon, Siraj M. Ali, Laurie M. Gay, et al.. (2014). A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib. Case Reports in Oncology. 7(3). 628–632. 10 indexed citations

18.

McLaren, Paul J., Stephan Ripke, Kimberly Pelak, et al.. (2012). Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Human Molecular Genetics. 21(19). 4334–4347. 44 indexed citations

19.

Erlich, Rachel, Xiaoming Jia, Scott Anderson, et al.. (2011). Next-generation sequencing for HLA typing of class I loci. BMC Genomics. 12(1). 42–42. 110 indexed citations

20.

Erlich, Rachel, Rebecca C. Fry, Thomas J. Begley, et al.. (2008). Anc1, a Protein Associated with Multiple Transcription Complexes, Is Involved in Postreplication Repair Pathway in S. cerevisiae. PLoS ONE. 3(11). e3717–e3717. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact